- Home
- DBL vs PYXS Comparison
DBL vs PYXS Comparison
Compare DBL & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DBL | PYXS |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.3M | 243.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | DBL | PYXS |
|---|---|---|
| Price | $15.36 | $4.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 61.0K | ★ 646.6K |
| Earning Date | 01-01-0001 | 11-03-2025 |
| Dividend Yield | ★ 8.67% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,820,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.75 | $0.83 |
| 52 Week High | $15.70 | $5.55 |
Technical Indicators
Market Signals| Indicator | DBL | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 46.14 | 48.71 |
| Support Level | $15.26 | $4.10 |
| Resistance Level | $15.49 | $4.58 |
| Average True Range (ATR) | 0.15 | 0.38 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 29.98 | 30.05 |
Price Performance
Historical ComparisonAbout DBL DoubleLine Opportunistic Credit Fund of Beneficial Interest
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.